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Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have developed an inducible dual-recombinase system by combining flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies to improve GEMMs of pancreatic cancer. This enables investigation of multistep carcinogenesis, genetic manipulation of tumor subpopulations (such as cancer stem cells), selective targeting of the tumor microenvironment and genetic validation of therapeutic targets in autochthonous tumors on a genome-wide scale. As a proof of concept, we performed tumor cell-autonomous and nonautonomous targeting, recapitulated hallmarks of human multistep carcinogenesis, validated genetic therapy by 3-phosphoinositide-dependent protein kinase inactivation as well as cancer cell depletion and show that mast cells in the tumor microenvironment, which had been thought to be key oncogenic players, are dispensable for tumor formation.
Pancreatic ductal adenocarcinoma (PDAC) is a fearsome disease, with a mortality rate >95% that has remained unchanged for decades 1 .
GEMMs that faithfully recapitulate the histological, molecular, genetic and clinical hallmarks of human PDAC have been developed [2] [3] [4] [5] . All are based on pancreatic expression of oncogenic Kras G12D or Kras G12V , which induce pancreatic intraepithelial neoplasias (PanINs) that progress to aggressive metastatic PDAC [2] [3] [4] [6] [7] [8] [9] . These GEMMs have elucidated the natural biology of pancreatic cancer, revealed potential diagnostic and therapeutic targets 10, 11 and highlighted the importance of the tumor stroma for PDAC maintenance, immune evasion and drug resistance 5, [12] [13] [14] .
However, classical Cre-loxP-based GEMMs rely on a single Cremediated recombination step to activate mutant Kras expression and do not allow genetic modeling and manipulation of sequential multistep tumorigenesis and tumor heterogeneity, which are important hallmarks of the disease. A single-step approach does not enable genetic validation of possible targets by blocking PanIN progression or treating established PDAC, nor does it enable genetic investigation of resistance mechanisms or manipulation of the tumor microenvironment.
We addressed these limitations by generating a 'next-generation' mouse model that allows controlled independent or sequential manipulation of genes involved in the development and maintenance of PDAC.
RESULTS

Sequential genetic manipulation of the pancreas
To create a dual-recombinase system (DRS), we generated transgenic mice expressing Flp-recombinase directed by the mouse Pdx1 promoter 15 (Pdx1-Flp; Supplementary Fig. 1a,b) . A Flp-activated alkaline phosphatase reporter allele (FSF-R26 hpAP/+ ) revealed recombination in pancreatic islets, ducts and acini, and we observed extra-pancreatic recombination in bile duct, duodenum and stomach, paralleling established Pdx1-Cre lines 2, 15 ( Supplementary Fig. 1c-f and Supplementary Table 1) .
To manipulate Flp-recombined cells sequentially using Cre, we generated a latent tamoxifen-inducible allele (CreER T2 ) silenced by an FRT-stop-FRT (FSF) cassette under the control of the CAG promoter as a Rosa26 knock-in (FSF-R26 CAG−CreERT2/+ ; Supplementary Fig. 2a,b) . To activate CreER T2 expression and monitor tamoxifen-induced CreER T2 -mediated recombination in the Flp-lineage, we used the Pdx1-Flp line together with a dual-fluorescent tdTomato-EGFP-Cre reporter (R26 mT−mG ) that switches expression from tdTomato to EGFP after Cre recombination ( Supplementary Fig. 2c,d ). Tamoxifen treatment induced EGFP expression in pancreatic acini, ducts and islets; stromal cells remained unrecombined (Supplementary Fig. 2d ). Immunohistochemistry confirmed colocalization of EGFP with markers for acini (α-amylase), ducts (CK19) and islets (insulin) ( Supplementary Fig. 2e) ; we observed sporadic extrapancreatic recombination in stomach, duodenum and bile duct ( Supplementary Fig. 2c ,f and data not shown). There was no evidence of recombination in the absence of tamoxifen, excluding leaky Cre activity in this system.
Tamoxifen-inducible genetic manipulation of the whole animal Toxicity in non-neoplastic cells is a major limitation of many current drugs. It is thus important to evaluate the consequences of inactivating a specific therapeutic target or pathway in whole animals. To mimic drug treatment and reveal potential toxic side effects, we generated a CreER T2 deleter model, R26 CAG−CreERT2 , which ubiquitously expresses CreER T2 (Supplementary Fig. 3a) .
High-dose tamoxifen treatment resulted in efficient Cre recombination of the R26 mT−mG reporter in various tissues, at low dose in just a few cells, whereas untreated mice showed none ( Supplementary  Figs. 3b,c and 4) .
Activation of oncogenic Kras G12D induces metastatic PDAC To achieve conditional activation of oncogenic Kras in the Pdx1-Flp lineage, we generated a FSF-silenced latent Kras G12D knock-in allele (FSF-Kras G12D/+ ) ( Supplementary Fig. 5a,b) . Kras G12D expression from the endogenous promoter in Pdx1-Flp;FSF-Kras G12D/+ (KF) mice induced PanIN precursor lesions and PDAC originating from Pdx1-Flp-recombined cells, as confirmed by the FSF-R26 hpAP reporter (Fig. 1a,b) .
The KF and the classical Pdx1-Cre;LSL-Kras G12D/+ (KC) 2 mice showed similar patterns of PanIN progression and PDAC formation (Fig. 1a,c,d ). Tumor latency, morphology, survival time and rates of metastasis were nearly identical ( Fig. 1d and Supplementary  Fig. 5c-e) . PDAC in KF and KC mice were histopathologically indistinguishable, showing the full disease spectrum, from well-differentiated to undifferentiated tumors and typical liver and lung metastasis (Fig. 1a,b, Supplementary Fig. 5c -e and data not shown). Both KF and KC models thus faithfully recapitulate human PDAC 2, 12 .
To accelerate PDAC formation, we generated KPF mice, in which the tumor suppressor p53 is inactivated through use of an FRT-flanked Trp53 allele (Trp53 frt ) (Supplementary Fig. 6 ). We also crossed the KF model with a mouse line that lacks p53 in the whole body (Trp53 ∆ ) npg t e c h n i c a l r e p o r t s and compared PDAC formation, metastasis rates and survival with the classical KPC (Pdx1-Cre;LSL-Kras G12D/+ ;LSL-Trp53 R172H/+ ) model, which carries a p53 R172H gain-of-function alteration 12, 16 . Again, tumors were histopathologically indistinguishable, revealing the full spectrum of human PDAC, from well-to poorly-differentiated and anaplastic tumors (Supplementary Fig. 6a-c) . Median survival times and rates of metastasis were very similar ( Supplementary Fig. 6a-e) , and the number of metastatic lesions varied between one and several dozen in all models.
To assess extrapancreatic tumor development, we analyzed KF mice and observed sporadic noninvasive skin and bile duct papillomas and serrated duodenal adenomas in <10% of KF mice (Fig. 1e) ; by contrast, the incidence of skin papillomas is as high as 80% in KC mice 2 . Notably, we observed no extrapancreatic invasive carcinomas. Overall, the extrapancreatic pathologies of KF mice resembled those of the KC model 2 but occurred at much lower frequencies. Inactivation of p53 did not affect the frequency or invasiveness of extrapancreatic tumors, probably owing to the rapidity of PDAC development ( Supplementary Fig. 6a-c) .
These results indicate that the KF and KPF models phenocopy the widely used KC and KPC models 2, 16 and may improve on them by reducing unwanted extrapancreatic tumor development.
Sequential genetic manipulation of PanIN lesions and PDAC KF mice develop PanIN and PDAC. To target and manipulate these lesions at a chosen time point using Cre-loxP, we crossed the FSF-R26 CAG−CreERT2 allele into KF mice and used the R26 mT−mG -Cre reporter to visualize the secondary genetic alteration (Fig. 2a) . Tamoxifen-activation of CreER T2 resulted in efficient excision of tdTomato and induction of EGFP in PanIN lesions in vivo (Fig. 2b) 
Size (bp) 400 P a n I N 1 P a n I N 2 P a n I N 3 P a n I N 4 P a n I N 5 P a n I N 6 npg t e c h n i c a l r e p o r t s ( Fig. 2b and data not shown), excluding leaky Cre activity or spontaneous recombination events in this system. To investigate whether our model provides the opportunity to recapitulate crucial aspects of human multistep carcinogenesis, we uncoupled temporal activation of oncogenic Kras from elimination of p53. We activated CreER T2 by tamoxifen treatment in 2-month-old Pdx1-Flp;FSF-Kras G12D/+ ;FSF-R26 CAG−CreERT2/+ mice with and without loxP-flanked (floxed) Trp53 (Fig. 2c,d ) and analyzed tumor development 1 month later. Inactivation of p53 in a stage-specific fashion induced rapid formation of multifocal PDAC. Histopathology revealed tumors that were well-to-moderately differentiated or undifferentiated. Untreated Pdx1-Flp;FSF-Kras G12D/+ ;FSF-R26 CAG−CreERT2/+ ;Trp53 lox/lox littermate controls and tamoxifen-treated mice lacking the floxed Trp53 showed only PanIN lesions ( Fig. 2d and Supplementary Fig. 7) .
To investigate whether gene expression can be modulated in a stage-specific manner, including in established PDAC, we used a Cre-activatable lacZ reporter line (LSL-R26 Tva−i−lacZ ) 4 . CreER T2 activation by tamoxifen resulted in lacZ expression in PanIN and PDAC in vivo (Fig. 2e and Supplementary Fig. 8a-c) . Again, the tumor stroma showed no apparent recombination events. Importantly, we observed no difference in recombination efficacy between stroma-rich, well-differentiated tumors and undifferentiated PDAC lacking desmoplasia ( Fig. 2e and Supplementary Fig. 8c ).
To manipulate PDAC in vitro, we isolated and cultured tumor cells from tamoxifen-naive Pdx1-Flp;FSF-Kras G12D/+ ;FSF-R26 CAG−CreERT2 mice carrying the R26 mT−mG -Cre reporter. Administration of tamoxifen resulted in EGFP expression within 24 h (Supplementary Fig. 8d ).
The DRS enables validation of therapeutic targets
To test whether the DRS can be used to define and validate therapeutic targets in vivo, we crossed Pdx1-Flp;FSF-Kras G12D/+ ; FSF-R26 CAG−CreERT2/+ mice with conditional floxed Pdpk1 (encoding 3-phosphoinositide-dependent protein kinase 1 (Pdpk1)) knockout mice 17 . This enables tamoxifen-mediated deletion of Pdpk1 in Kras G12D -induced PanIN (Fig. 3a-c) . Pdpk1 is an important downstream effector of phosphoinositide 3-kinase and essential for Kras G12D -induced PDAC initiation 17 . However, it remains unclear whether Pdpk1 is also necessary for PDAC progression. To inactivate ;Pdpk1 lox/+ controls and analyzed pancreata in mice at age 9 months. Inactivation of both Pdpk1 alleles resulted in macroscopically normal pancreata with normal size and weight, whereas tamoxifen-treated heterozygous Pdpk1 lox/+ controls showed increased pancreatic weight and size and macroscopic signs of tumor development (Fig. 3b) . Pdpk1-deleted mice retained normal pancreatic tissue architecture and showed only sporadic PanINs, whereas pancreata from control mice were nearly completely replaced by tumorous tissue owing to induction of low-and high-grade PanIN lesions (Fig. 3c,d) . Thus, Pdpk1 ablation in PanIN-bearing animals blocked tumor progression almost completely. Notably, the few PanINs that were present in tamoxifentreated Pdpk1 lox/lox mice expressed Pdpk1 (Fig. 3c) , suggesting incomplete recombination of the Pdpk1 locus. This was confirmed by laser-capture microdissection and genotyping PCR, which showed the intact floxed Pdpk1 band (Fig. 3e) . Thus, Kras G12D -driven PDAC progression depends on intact Pdpk1 expression.
To investigate whether the DRS can be used to validate therapeutic targets in established invasive PDAC in vitro and in vivo, we crossed Pdx1-Flp;FSF-Kras G12D/+ ;FSF-R26 CAG−CreERT2 mice with conditional LSL-R26 DTA/+ mice, which carry a latent DTA allele (encoding diphtheria toxin A) (Fig. 3f) . This enables depletion of all Flp-recombined cells as a proof of concept.
Tamoxifen-mediated Cre activation and DTA expression in cultured PDAC cells led to extensive cell death and depletion of PDAC cells in vitro (Supplementary Fig. 9a-c) . To investigate the feasibility of PDAC depletion in vivo, we monitored PDAC formation in Pdx1-Flp;FSF-Kras G12D/+ ;FSF-R26 CAG−CreERT2 mice with (DTA) or without (control) the LSL-R26 DTA allele by high-resolution ultrasound. Mice with established tumors of comparable size were then enrolled and treated with tamoxifen to activate Cre and express DTA. Tamoxifen-mediated DTA induction led to rapid regression of tumor volume, whereas control mice showed rapid disease progression (Fig. 3f-h and Supplementary Fig. 9d ).
After 7-14 d tamoxifen treatment, mice in the conditional DTA cohort showed tumor regression, and pancreatic masses were rarely detectable by ultrasound, macroscopic pathological examination or histopathology (Fig. 3g-j and Supplementary Fig. 9d-f) . Other pancreata of the DTA cohort displayed some residual small tumor nodules, with histopathological signs of intact tumor tissue (Supplementary Fig. 9e,f) . As we expected, tamoxifen treatment resulted in pancreatitis and pancreatic atrophy due to DTA-mediated cell depletion of both neoplastic and normal pancreatic tissue (Fig. 3i,j and Supplementary Fig. 9e,f) . Histopathological analysis and abnormally elevated serum lipase concentrations of tamoxifentreated Pdx1-Flp;FSF-R26 CAG−CreERT2 ;LSL-R26 DTA mice without the oncogenic Kras G12D allele confirmed pancreatitis induction by DTA expression. Tamoxifen-treated control mice showed normal pancreatic histology, no signs of inflammation or atrophy and normal serum lipase levels (Supplementary Fig. 9g,h) .
To investigate whether tamoxifen or activation of CreER T2 itself affects PDAC growth, we also treated Pdx1-Flp;FSF-Kras G12D/+ ; FSF-R26 CAG−CreERT2 tumor cells and mice with the FSF-R26 CAG−CreERT2 allele but not the latent DTA allele with tamoxifen. These cells and tumors continued to grow after treatment (Fig. 3g,h and Supplementary Fig. 9b,c) . The effects thus depend on DTA expression and not Cre recombinase toxicity 18 . Fig. 10a-e) . However, the pro-or antitumorigenic function of mast cells is controversial [20] [21] [22] . We used the DRS method to evaluate the contribution of mast cells to pancreatic carcinogenesis. To deplete mast cells in vivo, we used the mast cell-deficient Cpa3 Cre/+ line, which is not based on Kit hypomorphism 23 . This line lacks both connective tissue and mucosal mast cells owing to Cre-mediated eradication of the entire mast cell lineage. In addition to mast cells, carboxypeptidase A3 (Cpa3) is weakly expressed in hematopoietic progenitors and splenic basophils 23 .
We verified mast cell deficiency in skin and pancreas of Cpa3 Cre/+ , as compared to wild-type mice (Fig. 4a,b) . We then analyzed mast cell infiltration and PanIN and PDAC formation in KF mice with and without Cpa3 Cre/+ (Fig. 4c-g ). Staining with toluidine blue and immunofluorescence staining of the high-affinity IgE receptor FcεRI revealed the absence of mast cells in PanIN and PDAC lesions of Pdx1-Flp;FSF-Kras G12D/+ ;Cpa3 Cre mice, whereas KF controls frequently showed mast cell infiltration (Fig. 4c,d,f,g ). To investigate the role of mast cells in PDAC initiation, we analyzed mice deficient and proficient in mast cells at 9 months old, when all grades of PanIN are present in the KF model (Figs. 1c and 4e) . The number and grade of PanIN were the same, regardless of the presence of mast cells (Fig. 4e) . We also analyzed some mice at age 12 months. These showed sporadic occurrence of invasive PDAC, again regardless of whether mast cells were present (Fig. 4f,g ).
Mast cells are therefore dispensable for PDAC formation. Previous reports have, however, described dramatically altered tumor development and growth in mast cell-deficient hypomorphic Kit-mutant mice (for example, Kit W−sh ), or mice treated with cromolyn, a mast cell stabilizer 20, 24, 25 . We investigated expression of the Kit protooncogene during pancreatic carcinogenesis and frequently observed Kit expression in PanIN and PDAC cells by immunohistochemistry (Supplementary Fig. 10f,g ). Kit expression in pancreas was also analyzed by lineage tracing with a tamoxifen-inducible Kit CreERT2 knockin mouse line 26 , revealing that Kit marks a distinct pancreatic cell population (Supplementary Fig. 10h ). The R26 mT−mG -Cre reporter indicated no leaky Cre activity in the absence of tamoxifen.
These data indicate that hypomorphic Kit mutations may contribute to the altered tumor phenotype of mast cell-deficient models in a mast cell-independent manner 23 .
To gain insight into gene expression changes associated with mast cell deficiency, we performed mRNA expression profiling of pancreatic tumors and obtained a statistically significant gene expression signature of mast cell deficiency in Pdx1-Flp;FSF-Kras G12D/+ ;Cpa3 Cre/+ mice using gene-set enrichment analysis (GSEA) (normalized enrichment score = −1.5837048; nominal P = 0.008152174; false discovery rate (FDR) q = 0.0096; see also Supplementary Results). mRNA expression analysis of genes relevant to PDAC revealed no significant (P < 0.05) changes due to mast cell ablation, except in those encoding C-X-C motif chemokine 13 (Cxcl13), fibroblast growth factor 21 (Fgf21) and interleukin 2 receptor-γ (Il2rg) (Supplementary Fig. 11a,b and data not shown). Only 155 probe sets (0.44%), corresponding to 108 annotated genes, showed significantly (P < 0.05) different changes (>2-fold) in mRNA expression between mast cell-deficient and mast cell-proficient pancreatic tumors (Supplementary Fig. 11c) . In addition to the aforementioned three gene products, cathepsin E and the mucin Muc5ac have been linked to pancreatic disease (Supplementary Fig. 11d) . Thus, cancer-relevant pathways are not broadly affected by mast cell deficiency, corroborating our finding that mast cells do not influence PDAC development.
DISCUSSION
Breakthroughs in cancer research, such as genomic analysis and highthroughput drug and genetic screening, are providing a wealth of resources and large, complex data sets. Understanding and interpreting the biological and clinical relevance of these resources is a significant challenge but holds the promise of breakthrough treatments for particularly difficult conditions, such as PDAC.
What has so far made it difficult to take full advantage of these developments is a means of realistically modeling and manipulating the developing tumor entity and its microenvironment. This is vital for the identification and assessment of candidate therapeutic targets. We have generated, characterized and validated a next-generation DRS that enables sequential genetic manipulation of PanIN and PDAC cells and the host on a genome-wide scale in vivo. Combining the Flp-FRT recombination system for tumor initiation with the 'universal' Cre-loxP system for secondary genetic manipulation provides researchers with new opportunities to model, manipulate and investigate diverse aspects of malignant tumors in whole animals. This includes rigorous genetic analysis of (i) genetic alterations in multistep carcinogenesis, (ii) tumor cell subpopulations such as cancer stem cells, (iii) the tumor microenvironment, (iv) immune cell subpopulations, (v) the metastatic niche of host organs, (vi) therapeutic targets and (vii) resistance mechanisms (Fig. 5) .
The PDAC stroma supports tumor growth and mediates drug resistance and is clearly relevant to future therapies 12, 14 . It is therefore important to understand the biology of the different stromal subcomponents. To demonstrate the utility of the DRS-based PDAC model as a means of targeting the tumor microenvironment, we investigated the role of mast cells and showed that they are dispensable for PDAC initiation and progression (Supplementary Results).
Besides evaluating stromal subpopulations, the DRS-based PDAC model enables sequential mutagenesis within tumor-initiating cells or precursor PanIN lesions, as previously used to study p53 loss during sarcomagenesis 27 . It also allows rigorous genome-wide testing of tumor cell-intrinsic therapeutic targets. Synthetic lethal interaction partners of oncogenic Kras 28 and multiple novel candidate genes and pathways identified via genome-wide small hairpin RNA-and transposon-based forward genetic screens and next-generation sequencing [28] [29] [30] demonstrate impressively that potential treatment targets are available. These await rigorous genetic validation in vivo.
We demonstrated secondary genetic targeting, thus mimicking therapeutic interventions, using a floxed Pdpk1 mouse line and a latent DTA allele as proof of concept. Our model thus provides an ideal complement for genome-wide mouse embryonic stem cell repositories and mutant lines with Cre-inducible somatic inactivation of every gene, enabling genome-wide target validation 31 . The synergistic power of these developments will spur the field.
Two groups have generated transgenic GEMMs that allow tetracycline (TET)-inducible expression of oncogenic Kras in pancreas and its time-specific inactivation 32, 33 . These showed that continuous oncogenic Kras activity is essential for tumor maintenance 32, 33 . Combined with Cre-loxP, Flp-FRT and other recombination systems such as Drerox, these TET-Kras mice, as well as novel embryonic stem cell-based PDAC models 34 , will further increase the possibilities of modeling and manipulating PDAC cells and their microenvironment.
In summary, we developed a next-generation Flp-FRT-based spontaneous model of Kras-driven stroma-rich PDAC that recapitulates npg major hallmarks of human PDAC with minimal extrapancreatic disease. The use of secondary modifications allows genetic dissection of the native biology of PDAC tumors and their associated stroma and rigorous genetic validation of candidate therapeutic targets. The DRS model can thus contribute directly to the development of new therapeutic strategies. Generation of tissue-specific Flp driver lines or viral Flp delivery 27, 35 will allow spatial and temporal control of gene expression in various cancer models. The DRS approach is highly versatile with wide applicability and has the potential to significantly advance cancer research.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Materials.
All cell culture reagents were obtained from Invitrogen (Groningen, the Netherlands). Primers were made by MWG (Ebersberg, Germany) and restriction endonucleases obtained from New England BioLabs (Mannheim, Germany). The E. coli strains TOP10 and Stbl3 (Invitrogen, Groningen, the Netherlands) were used for transformation and plasmid amplification. 4-Hydroxytamoxifen (H6278) and peanut oil (P2144) were purchased from Sigma (Deisenhofen, Germany). Unless otherwise stated, animals were on a mixed C57Bl/6;129S6/SvEv genetic background. The strains were interbred to obtain mice with activation of oncogenic Kras G12D in the pancreas as previously described 10 . Age-and sexmatched randomized animals were used as indicated, and no animals were excluded from analyses. All animal studies were conducted in compliance with European guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committees (IACUC) of Technische Universität München, Regierung von Oberbayern and the UK Home Office. 
Mouse strains and tumor models. LSL-Kras
Construction of the
Construction of targeting vectors and generation of FSF-R26 CAG−CreERT2
and FSF-Kras G12D knock-in mouse lines. Rosa26 targeting by a knock-in strategy was performed on the basis of plasmid pROSA26-1 as previously described 4 . A targeting vector containing a CAG promoter and a FRT-flanked transcriptional and translational stop cassette (FRT-stop-FRT; FSF) with a neomycin resistance gene 5′ of the CreER T2 expression cassette was generated by standard cloning procedures (Supplementary Figure 2a) . The targeting vector was linearized and electroporated into 129S6/SvEv embryonic stem (ES) cells. Cells were selected with 200 µg ml −1 Geneticin, and correctly targeted homologous recombined clones identified by PCR as described 4 . Correct recombination and single-copy insertion was verified by long-range and quantitative PCR, respectively. Germline transmission was achieved in 2/2 clones harboring the targeted allele. A three-primer PCR strategy (Supplementary Figure 2b) was used to genotype FSF-R26 CAG−CreERT2 animals as described 4 .
To generate a novel tamoxifen-inducible CreER T2 deleter mouse line (R26 CAG−CreERT2 ), which ubiquitously expresses CreER T2 , we deleted the FRTflanked transcriptional stop cassette in FSF-R26 CAG−CreERT2 animals using the R26 Flpo/+ (ref. 41) deleter line.
To construct the FSF-Kras G12D targeting vector, we used a Kras genomic clone, amplified the long and short arm of the Kras targeting vector by PCR and introduced a codon 12 aspartic acid mutation into exon 2 by sitedirected mutagenesis. Finally, an FSF cassette with a splice acceptor 3′ of the first FRT recombination site and a promoterless neomycin-encoding resistance cassette was introduced into the first intron of the Kras targeting vector (Supplementary Figure 5a) . All constructs were verified by sequencing. We electroporated the PacI-linearized targeting vector into 129S6/SvEv ES cells and selected appropriately targeted clones with 200 µg ml −1 Geneticin. Homologously recombined clones were identified by PCR and correct recombination, and single-copy insertion was verified by long-range PCR and quantitative PCR, respectively. Two clones were injected into blastocysts (Polygene, Rümlach, Switzerland). Germline transmission was achieved in 2/2 clones harboring the targeted allele. A three-primer PCR strategy ( Supplementary  Figure 5b) was used to genotype animals.
Fluorescence stereomicroscopy and quantification of metastasis frequency.
Macroscopic analysis of mouse tissues, PDAC and metastases was performed using a Zeiss Stemi 11 fluorescence stereomicroscope. At necropsy, all abdominal organs and the lungs were investigated macroscopically for metastases as described 17, 43 . For microscopic quantification of metastases at least three series of sections (100 µm between the different series) of paraffin embedded lungs and livers of 20 mice per genotype with PDAC were prepared, H&E stained and investigated for the presence of metastases by an examiner blinded to the genotype of the animals.
Fluorescence in situ hybridization (FISH). Metaphase spreads were prepared from splenocytes using standard protocols and fluorescence in situ hybridization was performed as described 44 . Probes specific for the Flp transgene were amplified using GenomePlex Complete Whole Genome Amplification (WGA) kit (WGA2, Sigma) and labeled directly with ChromaTide Texas Red dUTP (Invitrogen) using GenomePlex WGA Reamplification Kit (WGA3, Sigma) and custom-made dNTP mixture. Probes were then denatured for 10 min at 65 °C and preannealed for approximately 30-45 min at 37 °C. Slides were prepared 1 week in advance, to age metaphases at room temperature (RT) with a desiccant. Slides were then pretreated in prewarmed 2× SSC and pepsin (75 µl of 1% pepsin in 50 ml of 0.01 M HCl) at 37 °C for 5 min each. Slides were washed three times in 2× SSC for 3 min, and then treated for 10 min in formaldehyde fixative (1.25 ml of formaldehyde, 40% w/v and 2.5 ml of 1 M MgCl 2 , 50 mM MgCl 2 in PBS) at RT. Slides were washed three times in 2× SSC for 3 min, passed through an ethanol series and air dried. Slides were then denatured in 70% formamide, 2 × SSC for 1 min 30 s, at 63 °C and passed again through an ethanol series and air dried. Denatured preannealed probes were added to the slides, covered with coverslips, sealed with Fixogum rubber cement (Marabu) and incubated overnight at 37 °C. To remove unbound probes, slides were subjected to posthybridization washes and mounted in SlowFade (Invitrogen) with DAPI, overlayed with coverslip and sealed with nail varnish. Metaphases were scanned using an epifluorescence microscope equipped with a charge-coupled device (CCD) camera and narrow band-pass filters. Images were captured using the SmartCapture software (Digital Scientific, UK) and metaphases were karyotyped using the SmartType Karyotyper software (Digital Scientific).
Generation and culture of primary mouse PDAC cell lines. Primary dispersed mouse pancreatic cancer cells were established and cultivated as previously described 43 . PDAC cells were cultured in DMEM supplemented with 10% FCS and 0.1 or 0.5 µM 4-hydroxytamoxifen or vehicle (ethanol) to delete loxP-flanked sequences in vitro. Cell proliferation was quantified by cell counting on consecutive days. All cell lines were authenticated by genotyping and tested for mycoplasma contamination.
Tamoxifen treatment of mice. Mice were fed with tamoxifen-containing chow (400 mg tamoxifen citrate per kilogram chow; CreActive TAM400, LASvendi, Soest, Germany) for 2 or 4 weeks to activate CreER T2 .
High-resolution ultrasound. Mice were screened for tumors by abdominal palpation. Palpable tumors were verified by high-resolution ultrasound (Vevo 2100, VisualSonics). Animals with average tumor diameters greater than 5 mm were enrolled in the treatment study as described 17 . Tumor volumes were determined by automated three-dimensional (3D) B-mode imaging along the entire length of the tumor (VisualSonics). Reconstructed three-dimensional ultrasound imaging data sets were analyzed and tumor volumes were quantified using the integrated Vevo 2100 software package (VisualSonics) by an examiner blinded to the genotype of the animals. Macroscopic tumor perfusion was analyzed using the Doppler mode of the Vevo 2100 system. Quantitative reverse-transcriptase PCR. Total RNA was isolated from tissues using the RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer's npg
